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Abstract
Aim: Treat-to-target, randomized controlled trials have confirmed lower rates of
hypoglycaemia at equivalent glycaemic control with insulin degludec (degludec) ver-
sus insulin glargine 100 units/mL (glargine U100) in patients with type 1 (T1D) or
type 2 diabetes (T2D). Treat-to-target trials are designed to enable comparisons of
safety and tolerability at a similar HbA1c level. In this post hoc analysis of the
SWITCH 1 and 2 trials, we utilised a patient-level modelling approach to compare
how glycaemic control might differ between basal insulins at a similar rate of
hypoglycaemia.
Materials and Methods: Data for HbA1c and symptomatic hypoglycaemia from the
SWITCH 1 and SWITCH 2 trials were analyzed separately for patients with type
1 diabetes and type 2 diabetes, respectively. The association between the individual
patient-level risk of hypoglycaemia and HbA1c was investigated using a Poisson
regression model and used to estimate potential differences in glycaemic control with
degludec versus glargine U100, at the same rate of hypoglycaemia.
Results: Improvements in glycaemic control increased the incidence of
hypoglycaemia with both basal insulins across diabetes types. Our analysis suggests
that patients could achieve a mean HbA1c reduction of 0.70 [0.05; 2.20]95% CI (for
type 1 diabetes) or 0.96 [0.39; 1.99]95% CI (for type 2 diabetes) percentage points
(8 [1; 24]95% CI or 10 [4; 22]95% CI mmol/mol, respectively) further with degludec than
with glargine U100 before incurring an equivalent risk of hypoglycaemia.
Conclusion: Our findings suggest that patients in clinical practice may be able to
achieve lower glycaemia targets with degludec versus glargine U100, before incurring
an equivalent risk of hypoglycaemia.
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1 | INTRODUCTION
Tight glycaemic control is important to reduce the risk of diabetes-
related complications and the associated morbidity, mortality and
healthcare costs.1,2 Glycaemic control requires a delicate balancing
act between keeping blood glucose levels close to normal, and mini-
mizing the risk of hypoglycaemia.3 Consequently, hypoglycaemia is
the main limiting factor to achieving optimal glycaemic control in clini-
cal practice, with implications for diabetes management and clinical
outcomes.4 Insulin degludec (degludec) has the longest half-life of cur-
rently marketed insulin analogues.5 The stable and consistent duration
of the blood glucose-lowering action of insulin degludec (degludec)
has the potential to minimize fluctuations in a patient's blood glucose
levels.6 An assessment of two pharmacodynamic studies confirmed
consistently lower relative within-day (estimated treatment ratio
[degludec/glargine U100]: 0.61 [0.54; 0.69]95% CI) and between-day
variability (variance ratio [glargine U100/degludec]: 12.50 [7.14;
21.74]95% CI) in glucose-lowering effect with degludec versus insulin
glargine 100 units/mL (glargine U100), while accounting for potential
experimental confounders.7 Randomized controlled trials (RCTs) sug-
gest that these pharmacological properties translate into less frequent
hypoglycaemia with degludec versus glargine U100 at equivalent
glycaemic control, across a broad spectrum of patients with
diabetes.8-11
RCTs have established that intensive glycaemic control,
targeting a lower HbA1c level through more aggressive insulin dose
titration and/or the use of additional antihyperglycaemic agents,
increases the risk of hypoglycaemia.12-14 However, the relationship
between treatment regimen intensity and hypoglycaemia funda-
mentally differs from the relationship between glycaemic control
and hypoglycaemia. The association between glycaemic control and
hypoglycaemia rates in insulin-treated patients with diabetes has
been investigated by a small number of RCTs that have shown an
inverse relationship between end-of-trial HbA1c level and
hypoglycaemia rates.15,16 Treat-to-target RCTs are designed to
enable the comparison of safety endpoints, such as hypoglycaemia
rates, at glycaemic parity, but this in turn confounds our under-
standing of the relative risks of hypoglycaemia for comparators at
different HbA1c levels. Less is known about this relationship out-
side of the well-controlled, clinical trial setting under conditions of
routine clinical care. Observational studies show an inconsistent
relationship between glycaemic control and hypoglycaemia rates in
patients with diabetes.17-19 These inconsistencies most probably
reflect inter-individual differences in hypoglycaemia propensity,20
in combination with varying patient tolerance and awareness
thresholds of hypoglycaemic events and a tendency to titrate insulin
to this individual threshold of hypoglycaemia (rather than to a
glycaemic target).
According to the US Food and Drug Administration guidance on
study design for the investigation of new treatments for diabetes, the
aim should be to achieve similar levels of glycaemic control in the new
and comparator treatments to enable a better comparison of safety
endpoints, such as hypoglycaemia, and thus establish comparable
risk–benefit profiles.21 Such treat-to-target study designs have limited
utility for comprehensive evaluations of treatment efficacy, as dosing
and/or treatment intensification are manipulated in order to achieve
the same glucose target with each treatment. However, a converse
approach of comparing glycaemic control at similar incidence rates of
defined safety endpoints would be unethical, as in order to obtain a
robust comparison potentially damaging adverse events would need
to be induced rather than avoided. Furthermore, high levels of inter-
individual variability in hypoglycaemia propensity,20,22 the influence
of lifestyle and/or stochastic factors on individual hypoglycaemia
rates,20 and relatively low rates of hypoglycaemia would complicate
the titration of insulin to target rates of hypoglycaemia.
In the current post hoc analysis, we utilized a patient-level model-
ling approach and data from the SWITCH trials to compare how
glycaemic control might differ between basal insulins at a similar rate
of hypoglycaemia.
2 | MATERIALS AND METHODS
2.1 | SWITCH trial designs
The trial design and primary results of the SWITCH trials have been
previously published.10,11 In brief, SWITCH 1 (NCT02034513) and
SWITCH 2 (NCT02030600) were both randomized, double-blind, mul-
ticentre, two-period crossover, treat-to-target clinical trials in patients
with diabetes (please refer to Appendix 1 in the supporting informa-
tion for the trial designs). In SWITCH 1, patients with type 1 diabetes
(T1D) (N = 501) received a basal–bolus regimen with mealtime insulin
aspart (two to four times daily); in SWITCH 2, patients with type 2 dia-
betes (T2D) (N = 721) received basal-only insulin therapy with or
without oral antidiabetic drugs (OADs); all pretrial OADs were contin-
ued at their pretrial dose. Both trials enrolled participants with a high
risk of hypoglycaemia (refer to Table 1), reflecting the patients seen in
clinical practice. Baseline characteristics of patients in the SWITCH
trials are summarized in Table 1.
In both trials, patients were randomized 1:1 to receive either
once-daily degludec (100 units/mL) for 32 weeks followed by glargine
U100 for a further 32 weeks, or vice versa. Patients attended up to
14 scheduled clinic visits where blood samples were taken for a cen-
tral laboratory measurement of HbA1c (refer to Appendix 1 for the
visit schedule). The primary endpoint was the rate of symptomatic
hypoglycaemia during the maintenance periods (weeks 16–32 and
weeks 48–64). The titration periods (weeks 1–16 and weeks 32–48)
were included to ensure complete washout of previous therapies,
minimize the effect of treatment switch on hypoglycaemia rates, and
facilitate an accurate comparison of safety endpoints at stable insulin
dose and glycaemic control.
Symptomatic hypoglycaemia was defined in both studies as
severe (according to the American Diabetes Association definition as
requiring third-party assistance)23 or blood glucose-confirmed
(<3.1 mmol/L [56 mg/dL]) symptomatic hypoglycaemia. Suspected
events of severe hypoglycaemia were confirmed by an external,
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blinded, event adjudication committee. The design and primary find-
ings of SWITCH 1 and 2 are summarized in Table 2.
Both trials were conducted in accordance with the Declaration of
Helsinki and International Conference of Harmonisation Good Clinical
Practice.24,25 Before trial initiation, protocols, consent forms and
patient information sheets were reviewed and approved by the appro-
priate health authorities and an independent ethics committee or
institutional review board at each site. Written informed consent was
obtained from all participating patients.
2.2 | Post hoc analysis of the SWITCH trials
Data were analyzed separately for patients with T1D and for
those with T2D. The study population included all patients with
at least one postbaseline HbA1c measurement until treatment
discontinuation or end of trial. Appendix 2 (see the supporting infor-
mation) presents a schematic illustration of the data, utilized in these
post hoc analyses, for hypoglycaemia and HbA1c at three fictional
clinic visits.
2.2.1 | Patient-level association between
glycaemic control and hypoglycaemia
Frequency of symptomatic hypoglycaemia between scheduled clinic
visits was analyzed for each patient group using a Poisson regression
model with treatment, treatment period, sequence and time of dosing
as fixed effects. The interaction between treatment and HbA1c at the
end of each interval (between scheduled clinic visits) was included as
covariate, patient as random effect, and interval duration as offset.
2.2.2 | Estimated difference in glycaemic control at
the same rate of hypoglycaemia
Differences in glycaemic control (change in HbA1c) between degludec
and glargine U100 at the same rate of hypoglycaemia were deter-
mined from the estimated rate ratios (ERRs) of symptomatic
hypoglycaemia in the maintenance periods of the SWITCH trials and
this model (described above). ERRs were applied to the modelled
patient-level associations between hypoglycaemia and HbA1c
reduction to estimate the increase in hypoglycaemia for a standard
(1.0 percentage point [11 mmol/mol]) decrease in HbA1c for each
treatment in the SWITCH trials using the following calculation:
1/(−log[a] * log[b]), where a is the slope of the patient-level associa-
tion between glycaemic control and hypoglycaemia with degludec in
the corresponding SWITCH trial, and b is the ERR (degludec/glargine
U100) for symptomatic hypoglycaemia in the maintenance periods of
the corresponding SWITCH trial. These estimates utilized the assump-
tion that hypoglycaemia is the limiting factor to glycaemic control in
clinical practice. It is worth noting that the patient-level models did
not rely on this assumption.
TABLE 1 Baseline characteristics of patients in SWITCH 1 and
SWITCH 2
Characteristic SWITCH 110 SWITCH 211
Full analysis set, N 501 720
Male, n (%) 269 (53.7) 382 (53.1)
Race, n (%)
White 462 (92.2) 578 (80.3)
Black 32 (6.4) 106 (14.7)
Asian 2 (0.4) 22 (3.1)
Other 5 (1.0) 14 (1.9)
Ethnicity: Hispanic or Latino, n (%) 51 (10.2) 262 (36.4)
Age, years 45.9 (14.2) 61.4 (10.5)
BMI, kg/m2 27.5 (4.8) 32.2 (5.6)
Duration of diabetes, years 23.4 (13.4) 14.1 (8.1)
HbA1c, % [mmol/mol] 7.6 (1.0)
[59 (11)]
7.6 (1.1)
[59 (12)]
eGFR, mL/min/1.73m2 90.0 (21.1) 78.3 (21.3)
Pretrial insulin, n (%)
NPH insulin 97 (19.4) 59 (8.2)
Insulin detemir 305 (60.9) 159 (22.2)
Glargine U100 1 (0.2)b 502 (69.7)
Rapid-acting insulin (CSII) 97 (19.4) 0 (0)
Pretrial treatment regimen, n (%)
Basal OD 0 (0) 606 (84.2)
Basal BID 0 (0) 114 (15.8)
Basal OD + 2–4 bolus injections 224 (44.7) 0 (0)
Basal BID +2–4 bolus injections 179 (35.7) 0 (0)
CSII 97 (19.4) 0 (0)
OADs at screening, n (%)
0 agents 100 (0) 150 (20.8)
1 agent 0 448 (62.2)
≥2 agents 0 122 (16.9)
Hypoglycaemia risk, n (%)
≥1 severe hypoglycaemic episodeb
in the last year
125 (25.0) 118 (16.4)
Moderate chronic renal failure 42 (8.4) 159 (22.1)
Hypoglycaemia unawareness 104 (20.8) 129 (17.6)
Exposure to insulin for ≥5 years N/A 356 (49.4)
Diabetes for ≥15 years 332 (66.3) N/A
Hypoglycaemic episodec in the
last 12 weeks
459 (91.6) 478 (66.4)
Abbreviations: BID, twice daily; BMI, body mass index; CSII, continuous
subcutaneous insulin infusion; eGFR, estimated glomerular filtration rate;
glargine U100, glargine 100 units/mL; N, number of patients; n, number in
sample; N/A, not applicable; NPH, neutral protamine Hagedorn; OAD, oral
antidiabetic drug; OD, once daily; %, percentage of patients.
Data are mean (standard deviation) unless otherwise stated.
aOne patient was randomized in error (treatment with glargine U100
within the last 26 weeks was an exclusion criteria in SWITCH 1).
bDefined as requiring third-party assistance.23
cDefined as symptoms of hypoglycaemia, blood glucose level ≤70 mg/dL,
or both.
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2.2.3 | Population-level association between
glycaemic control and hypoglycaemia
In addition to the patient-level modelling approach, a population-
level approach was also undertaken to enable comparison and to
facilitate discussion regarding the two approaches. Data for symp-
tomatic hypoglycaemic events and HbA1c in the maintenance
period were retrieved from the databases of the SWITCH trials. The
number of symptomatic hypoglycaemic events during the mainte-
nance period was analyzed using a Poisson model with patient as
random effect; treatment, period, sequence and time of dosing as
fixed effects; mean HbA1c in the maintenance period and mean
HbA1c in the maintenance period squared as covariates; and expo-
sure time to trial drug in each hypoglycaemia-counting period as an
offset term. The population-level associations between mean
HbA1c level and symptomatic hypoglycaemia rate were estimated
from these models.
3 | RESULTS
At baseline, the range of HbA1c was 4.1%–9.8% (21–84 mmol/mol) in
SWITCH 1 and 4.7%–10.8% (28–95 mmol/mol) in SWITCH 2 with a
median HbA1c of 7.6% (60 mmol/mol) in both trials (Figure 1). For
each randomized treatment, data from treatment periods 1 (weeks
1–32) and 2 (weeks 33–64; after treatment switch) were combined.
The most frequent HbA1c reduction was in the range of 0–1 percent-
age points (0–11 mmol/mol).
3.1 | Patient-level association between glycaemic
control and hypoglycaemia
Reduction in HbA1c increased the incidence of hypoglycaemic events
with both basal insulins across both diabetes types in the SWITCH tri-
als (Figure 2). For the same decrease in HbA1c, there was a smaller
TABLE 2 Design and primary findings of SWITCH 1 and SWITCH 2
SWITCH 110 SWITCH 211
Design Multicentre (USA: 84 sites; Poland: 6 sites),
randomized, double-blind, two-period
crossover
Multicentre (USA: 152 sites), randomized,
double-blind, two-period crossover
Participants N = 501 adults N = 721 adults
Inclusion criteria T1D ≥52 weeks, BB regimen or CSII
≥26 weeks, HbA1c ≤10%, BMI ≤45 kg/m2,
≥1 hypoglycaemia risk factor
T2D ≥26 weeks, basal insulin ± OADs
≥26 weeks, HbA1c ≤9.5%, BMI ≤45 kg/m2,
≥1 hypoglycaemia risk factor
Treatment Degludec or glargine U100 OD + mealtime
IAsp (2–4 times daily)
Degludec or glargine U100 OD ± OAD(s)
Randomization 1:1 to treatment sequence (degludec
followed by glargine U100 or glargine
U100 followed by degludec); 1:1 to
morning or evening dosing
1:1 to treatment sequence (degludec
followed by glargine U100 or glargine
U100 followed by degludec); 1:1 to
morning or evening dosing
Duration Two x 32-week treatment periods (titration:
weeks 1–16 and 32–48; maintenance:
weeks 16–32 and 48–64)
Two x 32-week treatment periods (titration:
weeks 1–16 and 32–48; maintenance:
weeks 16–32 and 48–64)
Titration BG target Basal insulin: 4.0–5.0 mmol/L (71–90 mg/dL);
IAsp: 4.0–6.0 mmol/L (71–108 mg/dL)
Basal insulin: 4.0–5.0 mmol/L (71–90 mg/dL)
Rate of symptomatic hypoglycaemiaa in
the maintenance periodb
Significantly lower with degludec versus
glargine U100 HR: 0.89 [0.85; 0.94]95% CI,
P < 0.001
Significantly lower with degludec versus
glargine U100 HR: 0.70 [0.61; 0.80]95% CI,
P < 0.001
Change in HbA1c from baseline after
32 weeks of treatmentc
Non-inferiority of degludec versus glargine
U100 confirmed for both treatment periods
Non-inferiority of degludec versus glargine
U100 confirmed for both treatment
periods
Abbreviations: BB, basal–bolus; BG, blood glucose; BMI, body mass index; CI, confidence interval; CSII, continuous subcutaneous insulin infusion; glargine
U100, glargine 100 units/mL; HR, hazard ratio; IAsp, insulin aspart; OAD, oral antidiabetic drug; OD, once daily; T1D, type 1 diabetes; T2D, type
2 diabetes.
aSymptomatic hypoglycaemia was defined as severe (requiring third-party assistance)23 as confirmed by an event adjudication committee or BG-confirmed
(<3.1 mmol/L [56 mg/dL]) accompanied by symptoms.
bPrimary endpoint; analysed using a Poisson model with patient as random effect; treatment, period, sequence, and time of dosing as fixed effects; and
logarithm of the observation time (100 years) as offset.
cAnalysed separately for each treatment period with a mixed model for repeated measurements including treatment, visit, sex, region, pre-trial insulin
regimen, and time of dosing as fixed effects, and age and baseline HbA1c as covariates; all fixed factors and covariates are nested within visit.
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relative increase in hypoglycaemic events with degludec compared
with glargine U100 for patients with T1D or T2D. For a 1.0 percent-
age point (11 mmol/mol) decrease in HbA1c, hypoglycaemia rates
increased relatively by: 18% [12; 25]95% CI with degludec versus 34%
[27; 42]95% CI with glargine U100 in patients with T1D, and 45% [31;
60]95% CI versus 67% [51; 85]95% CI, respectively, in patients
with T2D.
3.2 | Estimated difference in glycaemic control at
the same rate of hypoglycaemia
Our analysis suggests that patients could achieve a mean HbA1c
reduction of 0.70 [0.05; 2.20]95% CI (for T1D) or 0.96 [0.39; 1.99]95% CI
(for T2D) percentage points (8 [1; 24]95% CI or 10 [4; 22]95% CI mmol/
mol, respectively) further with degludec than with glargine U100
before incurring an equivalent risk of hypoglycaemia.
3.3 | Population-level association between
glycaemic control and hypoglycaemia
For T1D, there are broadly similar curvilinear relationships between
mean glycaemic control and the rate of hypoglycaemic events with
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F IGURE 1 Frequency distribution of HbA1c at baseline in
(A) SWITCH 1 and (B) SWITCH 2. Full analysis set
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F IGURE 2 Individual patient-level association between HbA1c
reduction and the incidence of hypoglycaemia in patients with
(A) type 1 diabetes or (B) type 2 diabetes, based on data from the
maintenance period of the SWITCH trials.
Glargine U100, insulin glargine 100 units/mL.
Based on the full analysis set. Frequency of overall symptomatic
hypoglycaemia was analyzed using Poisson regression with treatment,
treatment period, sequence and time of dosing as fixed effects. The
interaction between treatment and HbA1c at the end of each period
was included as covariate, patient as random effect and duration of
the period as offset. Data plotted are the estimated relative change in
incidence of symptomatic hypoglycaemia by HbA1c reduction and
95% confidence interval.
a Symptomatic hypoglycaemia was defined as severe (requiring third-
party assistance)23 as confirmed by an event adjudication committee
or blood glucose-confirmed (<3.1 mmol/L [56 mg/dL]) accompanied by
symptoms
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degludec and glargine U100, although the peak is more pronounced
and at a lower mean HbA1c level with glargine U100 compared with
degludec (Figure 3A). For T2D, the association between mean
glycaemic control and hypoglycaemic events varied substantially
between basal insulins, with a similar (as described above for T1D),
although less pronounced convex relationship with degludec, but a
concave relationship with glargine U100 (Figure 3B). This resulted in a
large divergence between basal insulins in the modelled number of
hypoglycaemic events in patients with near-normal glycaemic control
(HbA1c <6.0% [42 mmol/mol]), with a lower rate of these events for
degludec compared with glargine U100.
4 | DISCUSSION
In this post hoc analysis of SWITCH 1 and SWITCH 2, improvements
in glycaemic control increased the patient-level risk of hypoglycaemia
irrespective of the basal insulin treatment. In both T1D and T2D, how-
ever, a given level of reduction in HbA1c was associated with a
smaller relative increase in hypoglycaemic events in patients receiving
degludec compared with glargine U100. Based on the lower rates of
symptomatic hypoglycaemia with degludec versus glargine U100
reported in the SWITCH primary manuscripts, and the modelled asso-
ciations between glycaemic control and hypoglycaemia reported here,
our findings suggest that patients with diabetes could target a lower
individualized HbA1c goal with degludec than with glargine U100.
When interpreting the results of the present patient-level analyses, it
should be noted that these are for relative change in hypoglycaemia
frequency. Therefore, despite comparatively larger relative increases
in the frequency of hypoglycaemia for a given HbA1c reduction in
patients with T1D compared with T2D, in absolute terms, hyp-
oglycaemic events are expected to occur more frequently in patients
with T1D than in those with T2D.26
In clinical practice, a large percentage of patients with diabetes do
not achieve glycaemic targets. Results from the 2016/17 National Dia-
betes Audit indicate that, in England and Wales, only 30% of patients
with T1D and 67% of patients with T2D are achieving HbA1c <7.5%
(58 mmol/mol)27 while in the United States just 50% of adult patients
with diabetes are attaining HbA1c <7.0% (53 mmol/mol).28 Our findings
suggest that treatment with degludec might help to alleviate a limitation
to glycaemic control—hypoglycaemia—and thus might facilitate
improved glycaemic control in patients with diabetes when compared
with glargine U100 treatment. Our findings are supported by real-world
evidence of degludec providing better glycaemic control and a reduced
incidence of hypoglycaemia after switching from other basal insulins,
including glargine U100, under conditions of routine clinical
practice.29-32
There are numerous clinical risk factors for hypoglycaemia that
influence patient propensity towards hypoglycaemia, including age,
diabetes duration, co-morbidities, therapeutic regimen, impaired
hypoglycaemia awareness and experience of previous hypoglycaemic
events.20,33 Additionally, glycaemic variability may contribute to over-
all glycaemic control,34 with retrospective study data indicating that
high glycaemic variability is associated with poor glycaemic control
and also with the risk of severe hypoglycaemia.35 Furthermore, in a
post hoc analysis of clinical trial data, both intra- and inter-day
glycaemic variability were associated with hypoglycaemia risk in
insulin-treated patients with T2D.22 The crossover SWITCH trial
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F IGURE 3 Population-level association between mean HbA1c
level and hypoglycaemia rate in patients with (A) type 1 diabetes and
(B) type 2 diabetes based on data from the maintenance period of the
SWITCH trials.
Glargine U100, insulin glargine 100 units/mL; PYE, patient-year of
exposure.
Symptomatic hypoglycaemiaa in the maintenance period was analyzed
using a Poisson model with patient as random effect; treatment,
period, sequence and time of dosing as fixed effects; mean HbA1c in
the maintenance period and mean HbA1c in the maintenance period
squared as covariates; and exposure time to trial drug in each
hypoglycaemia counting period as an offset term. The population-
level associations between mean HbA1c level and symptomatic
hypoglycaemia rate were estimated from these models. Data shown
are the estimated population mean and the 95% confidence interval.
aSymptomatic hypoglycaemia was defined as severe (requiring third-party
assistance)23 as confirmed by an event adjudication committee or blood
glucose-confirmed (<3.1 mmol/L [56 mg/dL]) accompanied by symptoms
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design and the patient-level modelling approach utilized in the current
analysis will have minimized the influence of inter-individual variability
in hypoglycaemia propensity on these findings.
Unlike the patient-level results, the population-level associations
cannot assist in an estimation of the change in an individual's
hypoglycaemia rate with improved glycaemic control, but simply provide
an overall picture of these variables and their associations from a popula-
tion level. From a clinical viewpoint, our patient-level findings may be of
greater interest and/or value, as they can assist with clinical decision-
making and discussions between patients and physicians regarding
hypoglycaemia risk, regimen intensification and glycaemic targets.
Results from the population-level analysis are more difficult to
interpret as they suggest that the relationship between glycaemic
control and hypoglycaemia rate is different in patients with T2D
treated with glargine U100 compared with the other patient groups in
the SWITCH trials. Those with either very poor or near-normal
glycaemic control experienced fewer hypoglycaemic events than
those with intermediate control. However, patients with T2D treated
with glargine U100 who had near-normal glycaemic control experi-
enced the highest incidence of hypoglycaemia, with fewer events in
patients with intermediate or poor control. Our observation that
patients with poor glycaemic control had fewer hypoglycaemia events
seems intuitive. Meanwhile, the paradox of lower rates in those with
near-normal control with degludec (T1D and T2D) and glargine U100
(T1D only) may reflect high levels of compliance or excellent diabetes
self-management skills in certain patients or, perhaps, a subset of
patients with some preservation of the endogenous insulin response.
Alternatively, this paradox may signal a reduced awareness of
hypoglycaemia in a subset of patients with near-normal control,
relaxing the limitation of symptomatic hypoglycaemia to optimal
glycaemic control, presumably at the expense of a greater frequency
of asymptomatic events. These findings exemplify the difficulty in
interpreting population-level associations from a clinical standpoint
because of bidirectional associations between glycaemic control and
hypoglycaemia rates, in combination with high levels of variability
between patients in their propensity towards hypoglycaemia at a
given HbA1c level.
One of the main strengths of our post hoc analysis is that data
were extracted from two large rigorously designed, double-blind clini-
cal trials. Clinical trials are a powerful tool for developing evidence on
the safety and efficacy of a therapeutic intervention, but their limita-
tions can make it difficult to generalize their findings to more inclusive
populations of patients and diverse settings that reflect clinical prac-
tice.36 By contrast, real-world studies often lack the scientific rigour
of RCTs and may suffer from selection biases or confounding fac-
tors.36 These limitations have been overcome in the SWITCH trials to
some extent, where generalizability was enhanced through the inclu-
sion of patients who better represent those encountered in clinical
practice.10,11
Our analysis is subject to several limitations. Like all models, the
results largely depend on the underlying assumptions. While the pre-
sent analysis was conducted at the individual patient level and, there-
fore, may have accounted for a substantial proportion of consistent
inter-individual variation in hypoglycaemia risk, other factors,
including increased activity without additional carbohydrate,
decreased carbohydrate or caloric intake without compensation in
insulin dose, unplanned or strenuous exercise, alcohol consump-
tion and stress, which could have influenced hypoglycaemia rates,
were not captured.20 The SWITCH trials had a two-period, cross-
over design, whereby patients were randomized to a treatment
sequence (degludec followed by glargine U100 or glargine U100
followed by degludec) and, therefore, results in the second period
may have been influenced by events/treatment in the first period.
However, we adjusted our analyses for both period and sequence
effects and, consequently, we would not expect either to have
exerted a large influence on our results. In addition, as this was a
post hoc analysis, our findings need to be confirmed in further clin-
ical or real-world studies. However, as discussed previously, the
challenging design and ethical considerations prevent the compari-
son of glycaemic control between treatments at comparable rates
of hypoglycaemia in a clinical trial setting. Our analyses captured
symptomatic hypoglycaemic events, as per the SWITCH trial end-
points, but not all events are symptomatic and some patients have
a reduced awareness of the symptoms of hypoglycaemia. The
authors look forward to the availability of flash or continuous glu-
cose monitoring data from future clinical trials in this patient popu-
lation to assist with our understanding of hypoglycaemia risk
through the collection of data at high temporal resolution and
detection sensitivity.
In conclusion, the findings of this post hoc analysis suggest that
patients in clinical practice may be able to achieve lower glycaemic
targets with degludec compared with glargine U100, before incurring
an equivalent risk of hypoglycaemia. In patients who are suitable for
insulin intensification, this may give both the patient and clinician
greater confidence in titrating to a lower glycaemic target with
degludec versus glargine U100.
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